亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

未开盘 04-09 16:08:13

49.400

-1.650

-3.23%

最高51.800	最低49.400	成交量215.45万
今开51.000	昨收51.050	日振幅4.70%
总市值184.26亿	流通市值184.26亿	总股本3.73亿
成交额1.08亿	换手率0.58%	流通股本3.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":49.4,"timestamp":1775722093006,"preClose":51.05,"halted":0,"volume":2154500,"delay":0,"changeRate":-0.03232125367286971,"floatShares":373000000,"shares":373000000,"eps":-4.003577040884274,"marketStatus":"未开盘","change":-1.65,"latestTime":"04-09 16:08:13","open":51,"high":51.8,"low":49.4,"amount":108113386,"amplitude":0.047013,"askPrice":49.4,"askSize":6400,"bidPrice":49.38,"bidSize":7000,"shortable":3,"etf":0,"ttmEps":-4.228419762951126,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":0,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":51.05,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.6033594336194558,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"1125511109","title":"亚盛医药-B更新3月股份变动月报表，股本保持平稳","url":"https://stock-news.laohu8.com/highlight/detail?id=1125511109","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125511109?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:06","pubTimestamp":1775736367,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。报告显示，公司法定股本与上月保持一致，注册股本仍为500,000,000股普通股，面值每股USD 0.0001，对应法定/注册股本USD 50,000。本报告期内，公司已发行股份由上月底的373,322,192股增至373,324,692股，新增发行2,500股，均来自员工股份期权行使。库存股份数量继续保持为零，无购回或注销活动。期末公司股本总数为373,324,692股，与法定股本相比仍具备充足空间，整体股本结构保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158877959","title":"异动解读 | 创新药板块多重共振，亚盛医药-B盘中大涨12.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877959","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158877959?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:04","pubTimestamp":1775023471,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)今日盘中股价大幅上涨12.5%，表现强势。消息面上，今日创新药概念股集体走高，亚盛医药-B作为板块内个股跟随上涨。券商观点指出，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升。创新药板块正处于“业绩兑现、估值修复、会议催化”三重周期叠加的黄金窗口期，前期估值风险已得到较为充分的释放。此外，基本面方面，多家药企实现扭亏为盈。即将于4月召开的美国癌症研究协会年会（AACR）等重磅学术会议，也为中国创新药企带来了重要的催化预期，共同推动了板块及个股的上涨行情。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","09969","06955","01530","BK1191","BK1161","02637","01477","HK0000165453.HKD","02157","06855","09995","BK1574","02162","BK1583","159992","LU2328871848.SGD","LU1969619763.USD","BK1587","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811719","title":"“十亿美元分子”双核共振，亚盛医药-B(06855)加速全球创新价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811719?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:49","pubTimestamp":1774583348,"startTime":"0","endTime":"0","summary":"3月26日，亚盛医药-B2025年年度业绩正式出炉。“十亿美元分子”双核共振，夯实创新与全球化根基作为一家已经进入商业化加速阶段的创新药企业，亚盛医药在2025年最核心的价值研判锚点在于：不同于此前依靠耐立克“单点突破”，公司现阶段的全球商业化已步入“十亿美元分子”双核共振关键期。作为亚盛医药的第二款商业化产品，利生妥报告期内获批上市，为公司“十亿美元分子”双核共振奠定了重要基础，也成为公司业绩加速增长的关键一极。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","06855","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151997129","title":"异动解读 | 获券商看好业绩与管线，亚盛医药-B盘中大涨7.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151997129","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151997129?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:32","pubTimestamp":1774582361,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)今日盘中股价大幅上涨7.95%，引起了市场关注。消息面上，中信建投证券发布研究报告，维持对亚盛医药的“买入”评级。报告指出，公司2025年业绩符合预期，核心产品奥雷巴替尼营收实现大幅增长，另一产品利沙托克拉商业化前景优异。同时，公司多个全球三期临床试验持续推进，构成了未来的增长动力，增强了投资者对公司发展潜力的信心。财务数据显示，公司2025年产品销售收入同比增长90%，账上现金充足。券商报告预计公司未来几年收入将持续增长。这些积极因素共同推动了今日股价的显著上扬。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811531","title":"【券商聚焦】中信建投证券维持亚盛医药(06855)“买入”评级 基于商业化产品放量及国际化管线潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811531?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:17","pubTimestamp":1774581463,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，亚盛医药 2025年业绩符合预期，核心投资论点基于其商业化产品放量及国际化管线潜力。报告认为，公司核心产品奥雷巴替尼营收实现大幅增长，利沙托克拉商业化前景优异，且两款产品的多个全球三期临床持续推动，构成未来增长动力。另一产品利沙托克拉在上市后五个月实现销售收入7058万元。基于商业化放量及管线潜力，维持对亚盛医药-B的“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622788916","title":"亚盛医药-B(06855)2025年股东亏损同比扩大206.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622788916","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622788916?lang=zh_cn&edition=full","pubTime":"2026-03-26 08:46","pubTimestamp":1774485965,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)公告公布，截至2025年12月31日止年度，母公司拥有人应占亏损12.43亿元(人民币，下同)，同比亏损扩大206.53%；每股基本亏损3.49元。期内，集团收入5.74亿元，同比减少41.46%。耐立克（奥雷巴替尼）销售额同比增长81%至4.35亿元。期内，集团研发开支11.37亿元，同比增长20.08%。","market":"sh","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622588314","title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622588314?lang=zh_cn&edition=full","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1574","BK1161","06855","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620041734","title":"亚盛医药-B(06855)将在2026年美国癌症研究协会年会上公布四项最新临床前进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2620041734","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620041734?lang=zh_cn&edition=full","pubTime":"2026-03-18 08:17","pubTimestamp":1773793027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司共有四项临床前研究进展入选2026年美国癌症研究协会年会。此次会议将于2026年4月17日至 2026年4月22日在美国加州圣地亚哥举行。从群体科学与预防，到癌症生物学、转化医学与临床研究，再到幸存者关怀与权益倡导，AACR年会全方位展示了前沿的癌症科学与医学成果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415194.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","06855","BK4139","AAPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618030138","title":"每日卖空追踪 | 亚盛医药-B 03月12日卖空量成交7.35万股，卖空比例为4.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618030138","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618030138?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304239,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间03月12日，涨1.2%，卖空量成交7.35万股，较上一交易日减少57.34%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163612a463767f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163612a463767f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618138701","title":"亚盛医药-B03月12日主力净流入77.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2618138701","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618138701?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303354,"startTime":"0","endTime":"0","summary":"03月12日, 亚盛医药-B股价涨1.20%，报收47.22元，成交金额8173.7万元，换手率0.47%，振幅4.89%，量比0.75。亚盛医药-B今日主力资金净流入77.0万元，上一交易日主力净流出415.7万元。该股近5个交易日上涨8.45%，主力资金累计净流入543.2万元；近20日主力资金累计净流入3937.4万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312162032a46367c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312162032a46367c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112057635","title":"亚盛医药-B将于2026年3月25日公布2025年度未经审核财务业绩及业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1112057635","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112057635?lang=zh_cn&edition=full","pubTime":"2026-03-11 20:03","pubTimestamp":1773230627,"startTime":"0","endTime":"0","summary":"亚盛医药-B（股票代码：06855）计划于2026年3月25日披露其2025财年全年未经审计的财务报告，届时公司将同步更新最新业务动态。此次发布将涵盖公司核心研发进展、管线布局及战略规划等关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618984305","title":"亚盛医药-B盘中异动 股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618984305","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618984305?lang=zh_cn&edition=full","pubTime":"2026-03-10 09:42","pubTimestamp":1773106957,"startTime":"0","endTime":"0","summary":"2026年03月10日早盘09时42分，亚盛医药-B股票出现异动，股价急速上涨5.00%。截至发稿，该股报45.780港元/股，成交量17.72万股，换手率0.05%，振幅4.27%。资金方面，该股资金流入502.027万港元，流出150.428万港元。亚盛医药-B股票所在的生物技术行业中，整体涨幅为1.93%。亚盛医药-B公司简介：亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094237a45cebf3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310094237a45cebf3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618598432","title":"每日卖空追踪 | 亚盛医药-B 03月09日卖空量成交7.3万股，卖空比例为3.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618598432","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618598432?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045038,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间03月09日，跌3.67%，卖空量成交7.3万股，较上一交易日减少55.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163558a6b1c986&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163558a6b1c986&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110192741","title":"亚盛医药-B（06855）2月股份月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1110192741","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110192741?lang=zh_cn&edition=full","pubTime":"2026-03-06 06:11","pubTimestamp":1772748687,"startTime":"0","endTime":"0","summary":"亚盛医药-B（06855）3月5日公布截至2026年2月28日的股份变动月报表。报告显示，公司法定股本维持在5亿股，面值为每股0.0001美元，总额5万美元，较上月无变化。\n公司本月底已发行普通股总数为373,322,192股，与上月底持平，未出现新增发行或购回注销及库藏股变动。报告期内没有因期权或其他股权激励而新增发行股份，也无股份回购或购回注销事宜。\n截至2月末，公司股本结构整体保持稳定。公司在公告中确认遵守香港联合交易所有限公司的相关上市规则及法律法规要求。公告由公司秘书陈焯墁签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616375325","title":"亚盛医药盘中异动 股价大跌6.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616375325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616375325?lang=zh_cn&edition=full","pubTime":"2026-03-03 22:30","pubTimestamp":1772548226,"startTime":"0","endTime":"0","summary":"北京时间2026年03月03日22时30分，亚盛医药股票出现波动，股价快速下挫6.59%。截至发稿，该股报22.10美元/股，成交量191股，换手率0.00%，振幅0.00%。机构评级方面，在所有6家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。亚盛医药股票所在的生物技术行业中，整体涨幅为0.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322302697a7def0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030322302697a7def0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616437535","title":"每日卖空追踪 | 亚盛医药-B 03月03日卖空量成交9.77万股，卖空比例为3.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616437535","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616437535?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:30","pubTimestamp":1772526640,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间03月03日，跌5.69%，卖空量成交9.77万股，较上一交易日减少74.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163603a69cae60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303163603a69cae60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614357250","title":"每日卖空追踪 | 亚盛医药-B 02月25日卖空量成交5.37万股，卖空比例为5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614357250","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614357250?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:30","pubTimestamp":1772008242,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间02月25日，涨0.12%，卖空量成交5.37万股，较上一交易日减少67.88%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163600a4c6771a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225163600a4c6771a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614357270","title":"亚盛医药-B02月25日主力净流入295.8万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2614357270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614357270?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:15","pubTimestamp":1772007312,"startTime":"0","endTime":"0","summary":"02月25日, 亚盛医药-B股价涨0.12%，报收49.06元，成交金额4879.4万元，换手率0.27%，振幅2.61%，量比1.40。亚盛医药-B今日主力资金净流入295.8万元，上一交易日主力净流出267.3万元。该股近5个交易日上涨3.28%，主力资金累计净流入161.7万元；近20日主力资金累计净流入3680.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225161537a71d4575&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225161537a71d4575&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06855","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613788925","title":"每日卖空追踪 | 亚盛医药-B 02月23日卖空量成交1.16万股，卖空比例为3.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613788925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613788925?lang=zh_cn&edition=full","pubTime":"2026-02-23 16:30","pubTimestamp":1771835438,"startTime":"0","endTime":"0","summary":"亚盛医药-B北京时间02月23日，涨2.91%，卖空量成交1.16万股，较上一交易日减少75.73%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163528a4be7ea4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223163528a4be7ea4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.0509},{"period":"1month","weight":0.0515},{"period":"3month","weight":-0.101},{"period":"6month","weight":-0.3186},{"period":"1year","weight":0.3975},{"period":"ytd","weight":-0.0545}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.0183},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.2708},{"period":"ytd","weight":0.0048}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.857143,"avgChangeRate":0.112984},{"month":5,"riseRate":0.5,"avgChangeRate":0.054537},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}